Eiken Chemical Co., Ltd.
TTSE:45492,434.00
JPY
+17.00
(+0.70%)
ISIN
JP3160700005
Return %
Stock
S&P 500
1Y
1.88
14.20
3Y
66.37
81.12
5Y
22.68
68.34
Capital Structure
JPY
•
in mil. unless spec.Working Capital
JPY
•
in mil. unless spec.Growth Rates
JPY
•
in mil. unless spec.Quarterly Revenue
JPY
•
in mil. unless spec.Quarterly Earnings Per Share
JPY
•
in mil. unless spec.Quarterly Dividends Per Share
JPY
•
in mil. unless spec.Company Description
- CEO
- Yuji Segawa
- Full Time Employees
- 696
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 4-6 Kanda-Surugadai Tokyo TY Japan 101-0062
- IPO Date
- Jan 29, 1990
- Website
- eiken.co.jp
- Similar Companies
- Business
- Eiken Chemical Co., Ltd. (4549.T) manufactures and sells clinical diagnostic reagents, medical devices, and related equipment primarily in Japan and overseas markets. The company offers microbiological reagents for diagnosing microorganism infections including culture media, antimicrobial susceptibility tests, and rapid test reagents; urinalysis test strips detecting occult blood, protein, glucose, and other items; fecal immunochemical test (FIT) reagents and sampling bottles such as the OC Sensor series for colorectal cancer screening; immunological and serological reagents for infectious diseases, rheumatism, inflammation, atrophic gastritis, prostate specific antigens, and tumor markers; clinical chemistry reagents measuring biological components in blood serum and urine focused on lifestyle-related diseases; molecular diagnostic tests using proprietary Loop-mediated Isothermal Amplification (LAMP) technology including TB-LAMP for tuberculosis, Malaria-LAMP, and MINtS for lung cancer companion diagnostics; reagents and devices for food poisoning bacteria and environmental contamination testing; and various automated analyzers along with contract manufacturing of specialized equipment. Founded in 1939 and headquartered at 4-19-9 Taito, Taito-ku, Tokyo, Japan, Eiken Chemical operates through two main segments: clinical diagnostics serving hospitals, clinics, test centers, and screening facilities; and testing of food and environment for food/pharmaceutical companies. The company maintains subsidiaries for contract manufacturing of diagnostic reagents and pursues geographic expansion in Americas, EMEA (Europe, Middle East, Africa), and APAC regions, with overseas sales targeted to reach 15,100 million yen by FY2027. In May 2025, Eiken Chemical announced its new Medium-Term Management Plan for FY2025-FY2027 under the slogan "Challenges to Innovation," aiming for net sales of 46.9 billion yen, operating profit of 5.9 billion yen, ROIC of 8.1%, and ROE of 9.3% by FY2027 through portfolio restructuring, overseas expansion of FIT and TB-LAMP products, new product launches like MINtS expansions and Simprova applications, production site consolidations at Nogi Plant, and a shift to total payout ratio of 70% or higher. The plan includes strategic investments in Nanotis Corporation for saliva-based digital infectious disease testing, executive restructuring with new President & CEO Yuji Segawa effective June 2025, and tie-ups with Sysmex for global urinalysis growth and Tosoh for immunological reagents. In November 2025, the company cancelled 4 million treasury shares to optimize capital structure.